Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The "Plantibodies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ResearchAndMarkets.com's...
-
Expansion represents significant investment in North Carolina and is expected to create 700 new jobs in the state by end of 2030Enables manufacturing of medicines across company’s main therapeutic...
-
Dublin, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The "Joint Venture Deals in Pharmaceuticals and Biotechnology 2016-2025" has been added to ResearchAndMarkets.com's offering.This report contains a...
-
Boston, Nov. 17, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “Artificial Intelligence (AI) in Pharmaceuticals: Global Markets” is projected to grow from $3.8 billion in...
-
Dublin, Nov. 17, 2025 (GLOBE NEWSWIRE) -- The "mRNA Vaccine Drugs Development Services Market - Global Forecast 2025-2030" report has been added to ResearchAndMarkets.com's offering. mRNA vaccine...
-
Dublin, Nov. 14, 2025 (GLOBE NEWSWIRE) -- The "China's Evolution in Global Drug Development and Clinical Trials" report has been added to ResearchAndMarkets.com's offering. This report examines...
-
Dublin, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The "The Art of Technology Transfer in Drug Development: Developing and Building a Framework of Success (Aug 1, 2025)" training has been added to ...
-
NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, and CTI Clinical Trial and Consulting...
-
Certara announced the launch of TFL Studio, the first cloud-native module of its Phoenix Cloud solution.
-
Fabhalta and Vanrafia Phase III analyses, Fabhalta real-world treatment pattern data, and zigakibart Phase I/II trial showcase strength of IgA nephropathy (IgAN) portfolioC3 glomerulopathy (C3G)...